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Background:  The research on health behaviours of multiple sclerosis (MS) patients has 
been intensified in the last years. The proposal is to identify and intervene on modifiable factors, 
such as physical activity, weight control and dietary habits to delay disability and improve overall 
quality of life.  
Objective: This study aims to evaluate associations of dietary habits, body mass index 
(BMI) and body composition with the Expanded Disability Status Scale (EDSS). 
Material and methods: We investigated a cohort of 37 Portuguese adults with relapsing 
MS onset. They performed a nutritional evaluation, including food intake frequencies, height, 
weight and body composition [percentages of total body water (%TBW), soft lean mass (%SLM), 
fat body mass (%FBM) and phase angle], and were asked about their smoking status and physical 
activity. We also assessed demographic information and MS characteristics, including EDSS. 
Results: Seventeen (45.9%) patients were overweight or obese, but there was no 
statistically significant correlation between body mass index (BMI) and EDSS. Patients with higher 
EDSS had significantly lower phase angle (p=0.003), %TBW (p=0.024) and %SLM (p=0.024), as 
well as greater %FBM (p=0.025). Weekly intake of alcoholic beverages had a negative correlation 
with EDSS (p=0.006). There was also a significant negative correlation between EDSS and 
physical activity level (p=0.002). 
  Conclusions: We hypothesize that neurological disability leads to deleterious changes in 
body composition of MS patients. The %FBM seems to be a better marker of the risk of comorbid-
health conditions than BMI in MS patients and phase angle appears to have a considerable 
correlation with disability progression. We cannot conclude about the effective impact of dietary 
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sclerosis; n-3 PUFA, omega-3 long-chain polyunsaturated fatty acids; NHANES III, third National Health and 
Nutrition Examination Survey; PA, phase angle; SLM, soft lean mass; TBW, total body water; %FBM, 




Multiple Sclerosis (MS) is a progressive autoimmune-mediated disease but its cause still 
unknown. Previous research suggests that MS has a multifactorial nature, with involvement of 
genetic, immunological and environmental factors in a complex aetiology [1-4]. The environmental 
risk factors most associated with MS are low vitamin D status, prior infection with Epstein-Barr 
virus and tobacco smoking [2,3,5-8]. Tobacco smoking also seems to have a negative impact on 
MS progression [9,10].  
Although there are disease-modifying therapies that slow disease progression and 
prevent some symptoms, MS therapeutics remain limited and the disease leads to a progressive 
disability and a reduced quality of life [2,6,11]. In the past years, the investigation on health 
behaviours of MS patients has been intensified trying to identify and intervene on modifiable 
factors that could delay disability and improve the overall quality of life. 
 Physical activity probably generates important outcomes in MS patients, with both 
physical and mental improvements. Animal studies also suggest neuroprotective benefits.  
Unfortunately, a disease-modifying effect of physical activity in MS patients cannot be surely 
affirmed given the limited strength of evidence and the heterogeneous findings [12-14]. 
Studies have shown that a large body size during adolescence and young adulthood was 
associated with an increased risk of MS [7,15,16]. The pathophysiological mechanisms 
suggested seem to be complex, including change on adipokines’ secretion and higher prevalence 
of vitamin D deficiency among obese subjects. Data from experimental models suggested a 
negative impact of obesity in MS course and prognosis, but clinical investigation remain limited 
[17]. Some studies showed that prevalence of overweight or obesity is around 50% in MS patients 
with established diagnosis or at MS onset [18-21]. Interestingly, patients with significant disability 
are likely to have higher proportion of underweight [19,22,23].  
 The prevalence of fatigue and impaired muscle and movement functions is very high 
among MS patients [11] and there is no doubt that physical activity decreases steadily with 
disability progression [14,18,19]. Along with the possible abnormalities in skeletal muscle [24], 
these patients seems to have an increased fat mass and a reduced lean mass in the lower limbs 
[24,25]. However, studies reporting body composition of MS patients are limited and no 
association has been stablished with their disability progression. 
Currently, there is no direct evidence indicating a crucial role of nutrition in MS aetiology 
or progression. In the last years, the increasing amount of research shows the crescent interest 
in dietary habits as an important target in these patients [1,2]. 
 Omega-3 long-chain polyunsaturated fatty acids (n-3 PUFA) found in fish may be 
beneficial due to their neuroprotective, anti-inflammatory and immunomodulatory effects [1-
3,6,22,26]. Some authors suggested that n-3 PUFA enriched diet is helpful as a complementary 
 treatment to MS. This idea is supported by experimental studies, but clinical trials are inconclusive 
[1,6]. Other bioactive molecules frequently studied are polyphenols (found in vegetables and fruit) 
and carotenoids (mainly found in vegetables). Since oxidative stress is considered one of the 
most critical processes implicated in demyelination and axonal damage, these anti-oxidative 
substances could have a role in disease modulation. One of the most important polyphenols is 
resveratrol, that is found in nuts, some fruits and wine, which seems to have neuroprotective 
effects [2,3]. 
It has been suggested a promising effect of specific consumptions, such as caffeine 
[26,27] or alcohol [7,26,28] in MS progression. On the other hand, some eating habits seems to 
have a negative association with MS, including high intake of animal fat, smoked meat products, 
sugar, sweets, sweetened beverages or cow milk [2,3,5]. 
  Available data is still limited to make specific dietary recommendations for MS 
improvement and there are few studies on dietary intake habits and body composition of MS 
patients. In the present study, we aim to assess health behaviours in a cohort of Portuguese MS 
patients and analysed their association with MS status. Our primary goal is to evaluate the 
associations of dietary habits, body mass index (BMI) and body composition with the MS disability 





2.1. Study Population and Data Collection 
 
The study population included adult patients with MS diagnosis followed at the Neurology 
Department of Centro Hospitalar São João (CHSJ). MS diagnosis was established according to 
McDonald criteria [29].  At the time of their visit to neurology outpatient clinic between January 
and June of 2015, patients were asked to participate in the study and provided informed consent. 
After that, patients were guided to the nutrition unit of CHSJ to perform a nutritional evaluation 
and assess anthropometric and body composition measures. The nutritional evaluation was 
obtained through a face-to-face interview conducted by a nutritionist. 
The following data was collected from each patient’s interview: daily intake frequency of 
cow milk and/or yogurt, coffee, fruit, vegetables and weekly intake frequency of nuts (such as 
peanuts, almonds, pine nuts and walnuts), meat, fish and alcoholic beverages. We also asked 
the patients about their smoking status and classified them as never smoker, current smoker or 
former smoker. Physical activity was recorded using the short form of the International Physical 
Activity Questionnaire (IPAQ) and classified as low, moderate or high [30]. 
The anthropometric measures assessed were height (self-reported by each patient) and 
body weight (assessed with light clothing, without metal accessories nor shoes). We calculated 
their BMI by dividing weight (in kilograms) by height (in meters) squared and categorized it by 
Word Health Organization classification: <18.5 kg/m2 is considered underweight, 18.5 to <25 
 kg/m2 normal weight, 25 to <30 kg/m2 overweight and ≥30 kg/m2 obese. The body composition of 
each patient was obtained by the body composition analyser InBody720® (Direct Segmental Multi-
frequency Bioelectrical Impedance Analysis Method) and the values of total body water (TBW), 
in litres, soft lean mass (SLM) and fat body mass (FBM), in kilograms, were extracted to our 
database. The percentages of TBW (%TBW), SLM (%SLM) and FBM (%FBM) were calculated 
by dividing each absolute value by total weight. One patient didn’t fulfil this evaluation due to 
physical limitations. The phase angle (PA) was calculated directly from reactance and resistance. 
It represents a measure of cellular health and correlates with nutritional and functional status [31]. 
In medical records we assessed demographic information and MS characteristics, 
including year of diagnosis, relapsing or progressive disease onset, immunomodulatory drugs 
used, results of the last magnetic resonance imaging (MRI) scan (presence or absence of black 
holes and presence or absence of gadolinium-enhancing lesions) and neurological disability using 
the Expanded Disability Status Scale (EDSS) [32]. 
 
2.2. Statistical Analysis 
 
Data were analysed using IBM® SPSS Statistics for Windows, version 23.0 (Armonk, 
N.Y., USA: IBM Corp.). Kolmogorov-Smirnov test was used to assess normality. As all cardinal 
variables were non-normal distributed, the analysis was based on non-parametric tests. 
Descriptive statistics are presented as absolute (n) and relative (%) frequencies for 
categorical data or medians and percentiles 25th (P25) and 75th (P75) for quantitative data. 
Spearman’s correlation coefficient (rs) was used to measure the association between pair of 
quantitative variables and Mann-Whitney test was performed to compare mean ranks of two 
independent samples. Values of p<0.05 were considered statistically significant. 
This study was approved by the ethics committee of CHSJ, Porto, Portugal. 
  
 3. Results 
 
3.1. Study population characteristics 
 
A total of 37 adult MS patients were included. All patients were white, most of them were 
women (81.1%), with a median age of 37.5 years and median time since MS diagnosis of 5 years. 
All patients had a relapsing disease onset, with median EDSS of 1 and only two patients had no 
immunomodulatory treatment. More than one-half (55.6%) of the patients had black holes and 7 
(19.4%) patients had gadolinium-enhancing lesions on the last MRI scan. Additional information 
is showed in Table 1.  
 
3.2. Smoking status and physical activity 
 
About two-thirds (66.7%) of patients have never smoking and 7 (19.4%) patients were  
current smokers (Table 1). No significant association was found between smoking status and 
EDSS (Table 2). Less than one-third (28.6%) of patients reported low physical activity and 20 
(57.1%) patients reported moderate physical activity (Table 1). A statistically significant negative 




Twenty (54.1%) patients were normal weight, 12 (32.4%) overweight and 5 (13.5%) 
obese (Table 1). There was no statistically significant correlation between EDSS and BMI (Table 
3). 
 
3.4. Body composition 
 
 The medians (P25; P75) of TBW, SLM, FBM and PA by sex are showed in Table 1. 
Patients with higher EDSS had significantly lower %TBW (p=0.024), %SLM (p=0.024) and PA 
(p=0.003), as well as greater %FBM (p=0.025) (Table 3).  
 
3.5. Food intake frequencies 
 
Only the frequency of alcoholic beverages intake had a statistically significant negative 







 Table 1 
Demographic and clinical characteristics of study population. 
Sex [n (%)] 
    Female 




Age - years [median (P25 ; P75)] 37.5 (27.7 ; 47.3) 
Time since MS diagnosis - years [median (P25 ; P75)] 5 (1 ; 10) 
Immunomodulatory treatment [n (%)] 
    Interferon beta-1b 
    Interferon beta-1a 
    Glatiramer acetate  
    Fingolimod 
    Natalizumab 
    Fampridin 
    Teflunomide 










EDSS [median (P25 ; P75)] 1.0 (0.0 ; 2.5) 
Last MRI scan [n (%)] 
    Gadolinium-enhancing lesions 
Present 
Absent 










Smoking status [n (%)] 
    Never 
    Current 





Physical activity [n (%)] 
    Low  
    Moderate 





BMI categorization [n (%)] 
    Normal weight 
    Overweight 





TBW - litres [median (P25 ; P75)] 
    Female 
    Male 
 
30.3 (27.9 ; 32.1) 
42.8  (41.3 ; 43.5) 
SLM - kilograms [median (P25 ; P75)] 
    Female 
    Male 
 
38.8 (35.8 ; 42.3) 
55.0 (53.2 ; 55.9) 
FBM - kilograms [median (P25 ; P75)] 
    Female 
    Male 
 
22.3 (16.5 ; 29.0) 
10.8 (6.9 ; 21.1) 
PA [median (P25 ; P75)] 
    Female 
    Male 
 
5.1 (4.7 ; 5.6) 




 Table 2 
Characterization of EDSS according to smoking status (Mann-Whitney test). 
 Variable EDSS [median (P25 ; P75)] p 
Smoking status (n=36) 
    Never 
    Current or former 
 
1.0 (0.0 ; 2.5) 







Spearman’s correlation coefficients (rs) between EDSS and physical 
activity, BMI, body composition parameters and food intake frequencies. 
Variable EDSS [rs (p)] 
Physical activity (n=35) -0.513 (0.002) 
BMI (n=37) 0.271 (0.104) 
%TBW (n=36) - 0.376 (0.024) 
%SLM (n=36) - 0.376 (0.024) 
%FBM (n=36) 0.373 (0.025) 
PA (n=35) - 0.488 (0.003) 
Daily frequency intake:  
Cow milk and/or yogurt (n=37) - 0.011 (0.947) 
Coffee (n=37) 0.026 (0.877) 
Fruit (n=37) - 0.225 (0.181) 
Vegetables (n=37) - 0.019 (0.911) 
Weekly frequency intake:  
Meat (n=35) - 0.231 (0.182) 
Fish (n=35) - 0.111 (0.526) 
Nuts (n=35) - 0.100 (0.567) 





 4. Discussion 
 
 This study is one of the few studies presenting an overview of dietary habits and body 
composition in MS patients, as well as their associations with EDSS. We have also complemented 
the evaluation of health behaviours assessing physical activity and smoking status. 
Our sample presented a slightly less frequency of overweight and obesity among MS 
patients (45.9%) when compared to previous studies, which showed prevalence between 47.5% 
and 56.3% [18,19,21]. Although the considerable prevalence of overweight and obesity, a 
prospective study including 269 individuals with relapsing-remitting MS suggested that BMI had 
minimal impact on disability progression [21]. In agreement with those results, we found no 
significant association between BMI and EDSS. The association between BMI and MS disability 
status remains unclear. An unsolved question is whether the high prevalence of 
overweight/obesity in these patients develops independently or due to MS or its specific 
treatments. However, our results highlight the importance of weight status evaluation in these 
patients given the percentage of BMI values exceeding values recommended for health.  
 A study evaluating BMI and body composition in MS patients concluded that BMI 
threshold for obesity has a high specificity but underestimates true adiposity when compared to 
the percentage of body fat-defined obesity [33]. If we stratified our results of %FBM according to 
the values widely use as reference to define obesity (FBM ≥ 25% for men and ≥ 35% for women) 
[34], the proportion of patients classified as obese increase over 30% when compared to BMI 
classification (44.4% vs. 13.5%). These results may alert physicians to the importance of body 
composition evaluation as a marker of potential comorbidities’ risk, such as cardiovascular 
disease, and reduced health-related quality of life even in patients with BMI < 30 kg/m2.  
Previous research evaluating body composition found no significant differences between 
the %FBM of MS patients when they were compared with controls. There was no significant 
association between disability scales and components of body mass composition [25,35,36]. In 
contrast to those studies, we found a significant association between EDSS and %TBW, %SLM 
and %FBM. Patients with higher EDSS had significantly lower %TBW, lower %SLM and higher 
%FBM. These results suggest that neurological disability must lead to deleterious changes in 
body composition, increasing the risk of comorbid-health conditions.  
Since we didn’t have a control group, body composition parameters were compared with 
standardized values for sex and age groups described in population-based data from the third 
National Health and Nutrition Examination Survey (NHANES III) [37]. This comparative analysis 
intends to give us an estimate of how our sample approaches population standards. However, its 
interpretation may be limited because standard values proposed by NHANES III are not 
necessarily applicable to Portuguese population. Most of participants (75%) presented TBW (in 
litres) and FBM (in kilograms) within the 95% confidence intervals showed in NHANES III.  
Interestingly, 29 participants (82.9%) have a PA below the 95% confidence interval 
showed in NHANES III. Individuals with chronic diseases frequently present a lower PA than 
healthy subjects due to the influence of parameters like infection or inflammation [31]. Therefore, 
 the lower PA in most of our patients may reflect the disease negative effect on this parameter. 
Previous studies reported a predictive effect of PA on prognosis of several diseases (mortality 
and disease progression) [31]. For example, a study conducted on patients with amyotrophic 
lateral sclerosis showed that lower values of PA were significantly associated with shorter six-
month survival [38]. In our study, PA was significantly lower in participants with higher EDSS, 
bringing up the question of a possible relationship between PA and disability in MS patients. 
We found a significant association between EDSS and the frequency of alcohol 
consumption. The impact of alcohol consumption in MS is controversial and the information about 
alcohol use among MS patients is limited. In our study, patients with lower EDSS reported a 
significantly higher frequency of alcoholic beverages intake. This finding is supported by a large 
study in relapsing onset MS patients that reported an inverse association between alcohol 
consumption and the risk of reaching EDSS 6 [26]. Furthermore, moderate consumption of 
alcoholic beverages seems to have a potential anti-inflammatory effect due to ethanol’s properties 
on reducing pro-inflammatory cytokines synthesis or monocyte inflammatory responses [39]. 
Although we cannot exclude reverse causality, the association found by our group lead us to 
hypothesize a beneficial effect of alcoholic beverages consumption on neurological disability. 
Although a previous reported association of a higher coffee and fish consumption with a 
lower progression rate in relapsing onset MS [26], our results did not show any significant 
association between daily intake of coffee or fish and EDSS.  
Two large studies found a high prevalence of ever smoking among MS patients (over 
17% current smokers and 29% to 38% former smokers) [9,19]. One of them suggested an 
adverse effect of smoking in MS progression [9]. In our sample, 7 patients (19.4%) were current 
smokers and 5 (13.9%) were former smokers. Although the relative frequency of current smokers 
has been higher comparatively to those studies, we found no significant association between 
smoking status and EDSS. 
Regarding physical activity, a large study reported a predominant sedentary lifestyle 
among MS patients [19]. In contrast, 25 (71.4%) patients in our study reported moderate or 
vigorous physical activity. This proportion approaches the results of a survey study applied in 123 
women with MS, most of them (85%) ambulatory patients [18]. Therefore, the exclusive inclusion 
of ambulatory patients in our study may explain the higher level of physical activity. A cross-
sectional study had already suggest a positive effect of physical activity on reducing the risk of 
progression to EDSS 6 in relapsing onset MS [4]. In our study, patients with lower EDSS had a 
significantly higher physical activity level. We cannot conclude a beneficial effect of physical 
activity on delaying disability progression since the level of physical activity may be a reflection of 
functional status. Nevertheless, it is important to take physical activity in concern as a point of 
complementary intervention in MS patients. 
Our study has some limitations. The interpretation of dietary intake results was limited 
due to the absence of quantitative evaluation. Data that was self-reported in face-to-face 
interviews may have some inaccuracy related to patient and interviewer subjectivity. Given the 
small sample size, multivariable adjustment for confounders such as sex, age, years since the 
 diagnosis and immunomodulatory treatment was not viable. In addition, there were some missing 
values and we cannot exclude a change in health behaviours of MS patients over time. The main 
strength of this study is the assessment of dietary intake and body composition in MS patients, 
since there are few studies reporting that. Moreover, after nutritional evaluation the participants 
had opportunity to receive counselling on healthy dietary habits and general recommendations 




Our findings enhance the importance of assessing body composition as part of MS 
patients’ evaluation. We hypothesize that neurological disability leads to deleterious changes in 
body composition, namely increasing %FBM, which seems to be a better marker for risk of 
comorbid-health conditions than BMI in these patients. Furthermore, PA appears to have a 
considerable correlation with neurological disability. However, we cannot conclude that dietary 
habits have an effective impact on MS course. Large prospective studies are needed to infer 
causal relationships between specific dietary habits and MS outcomes, as well as to evaluate 
body composition changes during disease’s progression. It is important to clarify how changes in 
life-style may play a beneficial role on quality of life and MS course.  
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  Highlights 
 
 A high proportion of multiple sclerosis patients exceed body mass index and body 
composition values recommended for health. 
 
 Neurological disability seems to promote deleterious changes in body composition, 
namely increasing the percentage of fat body mass. 
 
 The percentage of fat body mass seems to be a better marker of the risk of comorbid-
health conditions than body mass index in these patients. 
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Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with
a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular
screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See   https://www.elsevier.com/graphicalabstracts
for examples. 
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in
accordance with all technical requirements: Illustration Service.
Highlights
Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article
and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and
include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See   https://www.elsevier.com/highlights
for examples.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and
multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may
be eligible. These keywords will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that
are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of
abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on
the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing
language help, writing assistance or proof reading the article, etc.).
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible
and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in
italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed
separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into
the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the
footnotes themselves separately at the end of the article.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork. 
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Indicate per figure if it is a single, 1.5 or 2­column fitting image. 
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage. 
• Please note that individual figure files larger than 10 MB must be provided in separate source files. 
A detailed guide on electronic artwork is available on our website: 
 https://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the
following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below): 
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'. 
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. 
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi. 
TIFF (or JPG): Combinations bitmapped line/half­tone (color or grayscale): a minimum of 500 dpi is required. 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low. 
• Supply files that are too low in resolution. 
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct
resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge,
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that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are
reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from
Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. For further
information on the preparation of electronic artwork, please see   https://www.elsevier.com/artworkinstructions.
Illustration services
Elsevier's WebShop (  http://webshop.elsevier.com/illustrationservices) offers Illustration Services to authors preparing to submit a
manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce
scientific, technical and medical­style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available,
where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the
illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on
separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes
below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described
elsewhere in the article. Please avoid using vertical rules.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the
abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may
be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation
of a reference as 'in press' implies that the item has been accepted for publication.
Reference management software
This journal has standard templates available in key reference management packages EndNote 
http://www.endnote.com/support/enstyles.asp and Reference Manager   http://refman.com/support/rmstyles.asp. Using plug­ins to
wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of
references and citations to these will be formatted according to the journal style which is described below.
Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow
us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in
the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known
(DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately
(e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the
same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products.
These include all products that support Citation Style Language styles (  http://citationstyles.org), such as Mendeley (
http://www.mendeley.com/features/reference­manager) and Zotero (  https://www.zotero.org/), as well as EndNote (
http://endnote.com/downloads/styles). Using the word processor plug­ins from these products, authors only need to select the
appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in
the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as
shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
 http://open.mendeley.com/use­citation­style/multiple­sclerosis­and­related­disorders
When preparing your manuscript, you will then be able to select this style using the Mendeley plug­ins for Microsoft Word or
LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style
is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume
number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal
will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the
author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:
Reference style
Text: All citations in the text should refer to: 
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication; 
2. Two authors: both authors' names and the year of publication; 
3. Three or more authors: first author's name followed by 'et al.' and the year of publication. 
Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically. 
Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....' 
List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference
from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication. 
Examples: 
Reference to a journal publication: 
Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. J. Sci. Commun. 163, 51–59. 
Reference to a book: 
Strunk Jr., W., White, E.B., 2000. The Elements of Style, fourth ed. Longman, New York. 
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Reference to a chapter in an edited book: 
Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith , R.Z. (Eds.), Introduction
to the Electronic Age. E­Publishing Inc., New York, pp. 281–304.
Reference to a website:
Cancer Research UK, 1975. Cancer statistics reports for the UK.
http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/ (accessed 13.03.03).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations:   http://www.issn.org/services/online­
services/access­to­the­ltwa/.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video
or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the
article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text
where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order
to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with
a preferred maximum size of 150 MB. Video and animation files supplied will be published online in the electronic version of your
article in Elsevier Web products, including ScienceDirect:   http://www.sciencedirect.com. Please supply 'stills' with your files: you
can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will
personalize the link to your video data. For more detailed instructions please visit our video instruction pages at 
https://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal,
please provide text for both the electronic and the print version for the portions of the article that refer to this content.
Patient Details
Every video submission must consist of high­resolution images and a consent form for publication for educational purposes signed by
the patient see form, please see the Patient Details section below. The Editors reserve the right to ask for additional video/s or video
modifications. 
Patient Details Studies on patients or volunteers require ethics committee approval and informed consent, which should be
documented in your paper.
If you wish to include images of patients or case details in an Elsevier publication, you will need to adhere to the following
requirements:
In order to comply with data protection and privacy rules, each individual who appears in any video, recording, photograph or case
report must be made aware in advance of the fact that such photographs are being taken or such video, recording or report is being
made and of all of the purposes for which you wish to use them and that individual (or next of kin in the case of children) must give
his/her explicit written consent. If such consent is made subject to any conditions (for example, adopting measures to prevent
personal identification of the person concerned), Elsevier must be made aware of all such conditions. Written consents must be
provided to Elsevier on request. 
The author is responsible for obtaining all necessary consents from patients for (i) the performance of any medical procedure
involved, as well as (ii) a release permitting our use of the relevant material. It is our insurers' preference that we do not have any
direct contractual relationship with the patients themselves. Please download the Patient consent form here
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar­
style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their
research in their own words and to help readers understand what the paper is about. More information and examples are available at 
 https://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e­mail to create an AudioSlides
presentation after acceptance of their paper.
Supplementary material
Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional
possibilities to publish supporting applications, high­resolution images, background datasets, sound clips and more. Please note that
such items are published online exactly as they are submitted; there is no typesetting involved (supplementary data supplied as an
Excel file or as a PowerPoint slide will appear as such online). Please submit the material together with the article and supply a
concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process,
then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure
to switch off the 'Track Changes' option in any Microsoft Office files as these will appear in the published supplementary file(s). For
more detailed instructions please visit our artwork instruction pages at   https://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this
Guide for Authors for further details of any item. 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
• E­mail address 
• Full postal address 
All necessary files have been uploaded, and contain: 
• Keywords 
• All figure captions 
• All tables (including title, description, footnotes) 
Further considerations 
• Manuscript has been 'spell­checked' and 'grammar­checked' 
• All references mentioned in the Reference list are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources (including the Internet) 
Printed version of figures (if applicable) in color or black­and­white 
• Indicate clearly whether or not color or black­and­white in print is required.
For any further information please visit our customer support site at   http://support.elsevier.com.
Availability of accepted article
This journal makes articles available online as soon as possible after acceptance. This concerns the accepted article (both in HTML
and PDF format), which has not yet been copyedited, typeset or proofread. A Digital Object Identifier (DOI) is allocated, thereby
making it fully citable and searchable by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it
is an unedited article. Subsequent production stages will simply replace this version.
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Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha­numeric
character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never
changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B): 
 http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.
Online proof correction
Corresponding authors will receive an e­mail with a link to our online proofing system, allowing annotation and correction of proofs
online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer
questions from the Copy Editor. Web­based proofing provides a faster and less error­prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the
e­mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the
typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for
publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent
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